A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

Inclusion Criteria:

• Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for atleast 26 weeks prior to the first administration of study intervention

• Candidate for phototherapy or systemic treatment for plaque psoriasis

• Need to meet criteria: Total body surface area (BSA) greater than or equal to (>=)1percent (%) at screening and baseline, and investigator global assessment (IGA) (overall) >=2 at screening and baseline and at least one of the following:scalp-specific investigator global assessment (ss-IGA) score >=3 at screening andbaseline, and/or static physician's global assessment of genitalia (sPGA-G) >=3 atscreening and baseline, and/or physician's global assessment of hands and feet (hf-PGA) score >=3 at screening and baseline

• Failed to respond to at least 1 topical therapy (example, corticosteroids,calcineurin inhibitors, and/or vitamin D analogs) used for treatment of psoriasis

• Confirmation of plaque psoriasis in a non-special area (example, areas excludingscalp, genital, palmoplantar) at screening and baseline

Exclusion Criteria:

• Nonplaque form of psoriasis (example, erythrodermic, guttate, or pustular)

• Dermatoses other than plaque psoriasis (such as contact dermatitis) or palmoplantarpustulosis of the palmoplantar area (if hf-PGA >=3 at baseline)

• Current drug-induced psoriasis (example, a new onset of psoriasis or an exacerbationof psoriasis from beta blockers, calcium channel blockers, or lithium)

• A current diagnosis or signs or symptoms of severe, progressive, or uncontrolledrenal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic,hematologic, rheumatologic, psychiatric, or metabolic disturbances

• Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients